London close: Stocks slip after stronger-than-expected US jobs data
London stocks fell as investors reacted to the release of a stronger-than-expected US non-farm payrolls report.
Source: sharecast.com
📰 Ip Group News
Page 2 - Ip Group News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ip Group. Real-time updates on events, politics, business and more.
4.06.2024 Alpine Select Ltd.: Monthly Update May 2024
Monthly Report - May 2024 Market commentary Risk assets advanced in May. Geopolitical tensions were disregarded as the global economy seems...
City Of United Kingdom Focuslight Technoligies Swiss Exchange Cheyne New Europe Fund Inc Liberty City Ventures Fund
Source: marketscreener.com
Mark Kleinman: Labour and Tories yet to win business over
This week Mark Kleinman tackles Labour and the Tories' attempts to win over business, IP Group investors and Thames Water.
Source: cityam.com
City grandee Flint faces investor unrest over IP Group role
Lombard Odier, IP Groups third-biggest shareholder, has expressed misgivings over Sir Douglas Flints stewardship of the early-stage investor in science-based companies, Sky News learns.
Source: sky.com
MARKET REPORT: International Workplace Group plunges as founder ditches £70m of shares
The FTSE 250 firm said chief exec Mark Dixon (pictured) offloaded 35m shares for around 196p each through investment vehicle Estorn Limited.
Source: dailymail.co.uk
London midday: Stocks stay down; Flutter Entertainment takes a hit
London stocks were still a little weaker by midday on Tuesday, as investors mulled the latest shop price inflation data.
Source: sharecast.com
London close: Stocks slip after hawkish Fedspeak
London close: Stocks slip after hawkish Fedspeak | Financial News
Source: lse.co.uk
IP Group Advances Share Buyback Program
IP Group plc (GB:IPO) has released an update. IP Group plc has actively engaged in its share buyback program, repurchasing 18,156 ordinary shares a...
Source: biztoc.com
STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024
STC-15 is the first METTL3 inhibitor to enter clinical development Clinical data will include safety, pharmacology, target modulation, and clinical activity CAMBRIDGE, England, May
Source: finanznachrichten.de
Synopsys, Inc. (NASDAQ:SNPS) Q2 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Synopsys Earnings Conference Call for the Second Quarter Fiscal Year 2024. At this time, all participants are in a listen-only mode.
Source: insidermonkey.com